TY - JOUR
T1 - ALDH5A1-deficient iPSC-derived excitatory and inhibitory neurons display cell type specific alterations
AU - Afshar-Saber, Wardiya
AU - Teaney, Nicole A.
AU - Winden, Kellen D.
AU - Jumo, Hellen
AU - Shi, Xutong
AU - McGinty, Gabrielle
AU - Hubbs, Jed
AU - Chen, Cidi
AU - Tokatly Latzer, Itay
AU - Gasparoli, Federico
AU - Ebrahimi-Fakhari, Darius
AU - Buttermore, Elizabeth D.
AU - Roullet, Jean Baptiste
AU - Pearl, Phillip L.
AU - Sahin, Mustafa
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2024/1
Y1 - 2024/1
N2 - Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a neurometabolic disorder caused by ALDH5A1 mutations presenting with autism and epilepsy. SSADHD leads to impaired GABA metabolism and results in accumulation of GABA and γ-hydroxybutyrate (GHB), which alter neurotransmission and are thought to lead to neurobehavioral symptoms. However, why increased inhibitory neurotransmitters lead to seizures remains unclear. We used induced pluripotent stem cells from SSADHD patients (one female and two male) and differentiated them into GABAergic and glutamatergic neurons. SSADHD iGABA neurons show altered GABA metabolism and concomitant changes in expression of genes associated with inhibitory neurotransmission. In contrast, glutamatergic neurons display increased spontaneous activity and upregulation of mitochondrial genes. CRISPR correction of the pathogenic variants or SSADHD mRNA expression rescue various metabolic and functional abnormalities in human neurons. Our findings uncover a previously unknown role for SSADHD in excitatory human neurons and provide unique insights into the cellular and molecular basis of SSADHD and potential therapeutic interventions.
AB - Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a neurometabolic disorder caused by ALDH5A1 mutations presenting with autism and epilepsy. SSADHD leads to impaired GABA metabolism and results in accumulation of GABA and γ-hydroxybutyrate (GHB), which alter neurotransmission and are thought to lead to neurobehavioral symptoms. However, why increased inhibitory neurotransmitters lead to seizures remains unclear. We used induced pluripotent stem cells from SSADHD patients (one female and two male) and differentiated them into GABAergic and glutamatergic neurons. SSADHD iGABA neurons show altered GABA metabolism and concomitant changes in expression of genes associated with inhibitory neurotransmission. In contrast, glutamatergic neurons display increased spontaneous activity and upregulation of mitochondrial genes. CRISPR correction of the pathogenic variants or SSADHD mRNA expression rescue various metabolic and functional abnormalities in human neurons. Our findings uncover a previously unknown role for SSADHD in excitatory human neurons and provide unique insights into the cellular and molecular basis of SSADHD and potential therapeutic interventions.
KW - Autism spectrum disorder
KW - Epilepsy
KW - GABA metabolism
KW - Mitochondrion
KW - Stem cell derived neurons
UR - http://www.scopus.com/inward/record.url?scp=85180608442&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2023.106386
DO - 10.1016/j.nbd.2023.106386
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38110041
AN - SCOPUS:85180608442
SN - 0969-9961
VL - 190
JO - Neurobiology of Disease
JF - Neurobiology of Disease
M1 - 106386
ER -